Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Detalles Bibliográficos
Autores principales: Hyak, Jonathan M., Huang, Ying, Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Byrd, John C., Kittai, Adam S., Jones, Dan, Miller, Cecelia R., Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/
https://www.ncbi.nlm.nih.gov/pubmed/35834733
http://dx.doi.org/10.1182/bloodadvances.2022007708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/
https://www.ncbi.nlm.nih.gov/pubmed/35834733
http://dx.doi.org/10.1182/bloodadvances.2022007708

Ejemplares similares